RECOMBINANT ADENOVIRUS EXPRESSING ALPHA-A-CRYSTALLIN GENE AND GENE THERAPY FOR RETINALVASCULAR DISEASE USING THE SAME
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jan 20, 2012
filing date -
Jan 21, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to a recombinant adenovirus expressing an αA-crystallin gene, and gene therapy for retinal vascular disease using the recombinant adenovirus. Gene therapy using the recombinant adenovirus comprising an αA-crystallin gene of the present invention increases the expression level of the αA-crystallin gene in the damaged retinal pericytes to suppress pericyte loss and death, retinal vascular leakage, and leukocyte adhesion surrounding retinal vessels, thereby protecting the pericytes. Therefore, it can be used for the prevention and treatment of various retinal vascular diseases including diabetic retinopathy.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully